Skip to contentB
Biofrontera Inc.
B
BFRIBiofrontera Inc. Q3 2024 · 10-Q
Revenue$9.01M$9.01M+1.3% vs Q3 2023 Net Income-$5.67M-$5.67MN/M vs Q3 2023 EPS Diluted-$0.98-$0.98N/M vs Q3 2023 Operating Income-$4,960,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biofrontera Inc. · CIK 1858685 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,208,000N/M Margins · derivedOperating margin-55.0%−3.1 pt vs Q3 2023
Net margin-62.9%+8.4 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end